Press Releases

GlobeNewswire, Inc.

First clinical data for dapolsertib monotherapy: initial results from the Phase II JASPIS-01 study of dapolsertib (MEN1703), a first-in-class oral dual PIM/FLT3 kinase inhibitor, in patients with relapsed/refractory (r/r) aggressive B-cell...

GlobeNewswire, Inc.

North Bethesda, Md., Nov. 04, 2026 (GLOBE NEWSWIRE) -- REdistribute, the MLS-owned joint venture that licenses MLS listing data for institutional use, today announced that it will partner directly with brokerages to fill coverage gaps in markets...

Governor of State of Hawaii

STATE OF HAWAIʻI KA MOKU ʻĀINA O HAWAIʻI JOSH GREEN, M.D. GOVERNOR KE KIAʻĀINA DEPARTMENT OF THE ATTORNEY GENERAL KA ʻOIHANA O KA LOIO KUHINA ANNE LOPEZ ATTORNEY GENERAL ATTORNEY GENERAL ANNE LOPEZ LEADS MULTISTATE EFFORT URGING CONGRESS TO PASS...

GlobeNewswire, Inc.

New CARTITUDE-4 subgroup analyses provide further insights into durable clinical outcomes with CARVYKTI in earlier-line treatment Updated data to be presented from first-in-human trial of LB2501, an investigational, off-the-shelf in vivo CAR-T...

GlobeNewswire, Inc.

Three iadademstat abstracts have been accepted for presentation Updated data from the ongoing Phase Ib ALICE-2 trial combining iadademstat with azacitidine and venetoclax in newly diagnosed, unfit AML patients showed a 95% overall response rate,...

GlobeNewswire, Inc.

HOUSTON, Nov. 04, 2026 (GLOBE NEWSWIRE) -- HMH Holding Inc. (“HMH” or the “Company”) (NASDAQ: HMH) today announced financial and operational results for the third quarter of 2026. Third Quarter Highlights Revenue of $171.1 million, down 21%...

GlobeNewswire, Inc.

CAMBRIDGE, Mass., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, disease-modifying T cell engagers in autoimmune diseases and...

GlobeNewswire, Inc.

LONDON and GAITHERSBURG, Md., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies and...

Louisiana Department of Agriculture & Forestry

News October 29, 2026 News article (Alexandria, La., October 27, 2026) —U.S. Department of Agriculture’s Rural Development recently announced nearly $25 billion in rural community investments nationwide in fiscal year 2026. These projects...

GlobeNewswire, Inc.

BERKELEY, Calif., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU) today announced that vispa-cel and CB-011 clinical abstracts have been accepted for two oral presentations and one poster presentation at the 2026...

GlobeNewswire, Inc.

14 abstracts accepted at ASH 2026, including three oral presentations featuring new data across mitapivat clinical programs New analyses from RISE UP Phase 3 trial of mitapivat in sickle cell disease show durable hemoglobin improvements for up to...

GlobeNewswire, Inc.

– 14 accepted revumenib abstracts, including 7 for oral presentation, reinforce Syndax’s scientific leadership in menin inhibition – – Revumenib abstracts highlight encouraging activity across multiple acute leukemia subtypes and settings,...

GlobeNewswire, Inc.

WELLESLEY HILLS, Mass., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical stage biotechnology company developing therapeutics for patients with immune-mediated diseases, today announced that it will present new clinical...

GlobeNewswire, Inc.

NEW IBERIA, La., Oct. 28, 2026 (GLOBE NEWSWIRE) -- On Tuesday, HII (NYSE: HII), America’s largest military shipbuilder and the global leader in autonomous seapower, celebrated a milestone in the production of ROMULUS unmanned surface vessels...

GlobeNewswire, Inc.

Two oral presentations featuring additional data from RALLY-MF Phase 2 trial of selcodebart (DISC-0974) in anemia of myelofibrosis (MF) and RESTORE-PV Phase 2 trial of DISC-3405 in polycythemia vera (PV) Oral presentation highlighting inhibition...

GlobeNewswire, Inc.

Ronde-cel achieved a 91% overall response rate and 77% complete response rate; median progression-free survival not reached and estimated 6-month duration of complete response of 92% in 44 patients with 3L+ R/R LBCL in the PiNACLE pivotal trial...

GlobeNewswire, Inc.

BEACON Trial Results Selected for Official ASH Press Program Initial Patient-Reported Outcomes Demonstrate Early and Sustained Improvements in Physical Function, Pain, Fatigue, Emotional and Social Well-Being and Symptom Severity U.S. Biologics...

EIN Presswire

Michael Galyen speaks with Dr. Sean Bouzigard of 100% Chiropractic about chiropractic care, common accident injuries, and getting checked out after a wreck.

Office of the Attorney General California Department of Justice

Senate’s Kids Online Safety Act allows states to continue critical work to protect children OAKLAND — California Attorney General Rob Bonta today joined a bipartisan coalition of 45 attorneys general in reaffirming support for the Senate version...

EIN Presswire

NEW ORLEANS, LA, UNITED STATES, October 19, 2026 /⁨EINPresswire.com⁩/ -- Unexpected street closures can create transportation challenges throughout the Greater New Orleans area, particularly in neighborhoods with narrow roadways, limited alternate...